GBI

Pharmaceutical and Medtech Market Intelligencegbihealth.com

GBI is a Shanghai-based enterprise SaaS provider of pharmaceutical and med-tech intelligence for the China market, offering pipeline tracking, KOL analytics, medtech data, and AI-powered social listening through its SOURCE, METRIX, DEVINT, and MediListen platforms.

Company typePrivate
Founded2002
HeadquartersShanghai, China
Headcount51–100
GTM typeB2B
OfferingSoftware

What GBI does

GBI (operating as General Biologic, legal entity GB Group Limited) is a Shanghai-based enterprise software company that delivers pharmaceutical and medical technology intelligence for the China market. The platform is organized around four core products: SOURCE, a pharma intelligence system providing China market news, data, and analytical tools; METRIX, a tool for KOL identification and commercial insights serving medical affairs, R&D, and sales/marketing teams; DEVINT, a medtech intelligence system with company- and product-level analytics; and MediListen, an AI-powered social listening platform for the medical field. Together these products address pipeline tracking, regulatory monitoring, competitive intelligence, KOL mapping, and social signal analysis for healthcare industry decision-makers.

The company primarily serves pharmaceutical companies, medical technology companies, and their internal medical/commercial teams, both domestic Chinese firms and global companies requiring China-specific market intelligence. GBI operates a subscription-based SaaS model with annual billing and custom enterprise pricing that is not publicly disclosed, distributed exclusively through direct enterprise sales without third-party resellers. Go-to-market is consultative and account-based, supported by phone and email channels plus LinkedIn presence for top-of-funnel awareness.

Underlying technology combines domain-specialized data aggregation (regulatory, clinical, product, and social) with AI-driven text processing in the MediListen module. The platform is delivered as a web application requiring login, with system requirements supporting modern desktop and mobile browsers. The company was founded in 2002, employs 51–100 people, and remains privately held with no disclosed institutional investors, acquisitions, or leadership transitions in the available record.

GBI firmographics

Firmographics

Name: GBI
Legal name: GB Group Limited
Website: http://www.gbihealth.com
Company type: Private
Founded year: 2002
Operating status: Operating
Headcount range: 51–100 employees
Short description: GBI is a Shanghai-based enterprise SaaS provider of pharmaceutical and med-tech intelligence for the China market, offering pipeline tracking, KOL analytics, medtech data, and AI-powered social listening through its SOURCE, METRIX, DEVINT, and MediListen platforms.
Ownership category
akta.pro rank

GBI industry classification

Industry

Product category: Pharmaceutical and Medtech Market Intelligence
NAICS: Software Publishers (513210)
akta.pro primary industry: Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
akta.pro secondary industry: B2B SaaS & Enterprise Personalization (CRM, Sales, Support) (HDAAAGAJ)

Keywords

Pharmaceutical intelligence
Medtech analytics
KOL tracking
Pharma market intelligence
Healthcare data analytics

Where GBI is headquartered

Location

Headquarters

HQ city: Shanghai
HQ country: China
HQ region: Asia

Offices1 record

Markets served

GBI business model

Business model

GTM type: B2B
Offering type: Software
Cost components: Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

Enterprise Software Subscriptions: GBI operates on a subscription-based SaaS model providing access to its intelligence platforms. Pricing is not publicly disclosed and requires direct inquiry, indicating enterprise-tier annual or multi-year subscription contracts typical of B2B pharma intelligence platforms.

Pricing tiers

Model	Billing	Price
Subscription	Annual	Enterprise subscription with custom pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

GBI product offering

Product offering

Core offering

GBI operates a portfolio of SaaS intelligence platforms — SOURCE, METRIX, DEVINT, and MediListen — that deliver China-focused pharmaceutical and medtech market intelligence, KOL tracking, and AI-driven social listening. The platforms provide industry professionals with news, data, and analytical tools for decision-making across drug pipeline monitoring, regulatory tracking, competitive analysis, and marketing strategy.

Product overview

GBI offers a unified platform of pharma and medtech intelligence products for the China market. The portfolio consists of four core products: SOURCE (pharma intelligence and analytics), METRIX (KOL and commercial insights tool), DEVINT (medtech intelligence), and MediListen (AI-powered social media analysis). Together, these products provide comprehensive coverage across pharmaceutical and medical technology sectors, with MediListen incorporating AI capabilities for social listening and real-world insight generation.

Differentiator

Problem solved

Functional benefit

Brands

SOURCE: Pharma intelligence system providing industry professionals with China market news, data, and analytical tools for decision-making.
METRIX
DEVINT
MediListen

Products and services

SOURCE

Companies that use GBI

Customer profile

Segments3 records

Ideal customer profiles3 records

GBI technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

GBI partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

GBI competitors and assessment

Company assessment

Direct peers

Citeline (Pharma Intelligence): Provides pharma pipeline, clinical trial, regulatory, and commercial intelligence products (e.g., Pharmaprojects, Trialtrove, Datamonitor Healthcare). Highly comparable to GBI's SOURCE and DEVINT offerings in scope, though with broader geographic coverage.
GlobalData: Provides data and analytics across pharma, healthcare, and medtech, including China-focused coverage. Overlaps with GBI's intelligence products for both pharma and medical device sectors.
Definitive Healthcare: Healthcare commercial intelligence platform focused on provider, patient, and therapeutic intelligence. Comparable in business model (B2B SaaS pharma/healthcare intelligence) though focused on US-centric data.
Evaluate (Norstella): Commercial pharma intelligence platform covering drug forecasts, pipeline valuation, and market access analytics. Comparable to GBI's commercial-intelligence positioning for pharma strategy and market access teams.
PharmCube (Pharnexcloud): China-native pharma data and intelligence platform offering drug pipeline, clinical trial, and competitive intelligence for the Chinese market. Direct competitor to GBI's SOURCE product within the same geographic niche.

Broad incumbents

IQVIA: Global clinical and commercial life sciences intelligence giant offering pipeline, RWD, and commercial analytics across all major markets including China. Directly overlaps with GBI's pharma intelligence scope but as part of a much broader portfolio rather than a China-only specialization.
Clarivate: Provides life sciences and IP intelligence including Cortellis, Derwent, and BioWorld. Comparable scope of pharma intelligence products and serves similar enterprise pharma/medtech customers globally.
Veeva Systems: Dominant life sciences CRM and data cloud platform used by global pharma. Relevant adjacent peer due to overlapping enterprise pharma customer base and data-centric SaaS delivery model.
Kantar Health (now part of Cerner/Oracle): Provides health market research, real-world evidence, and commercial insights to pharma and medtech companies. Overlaps with GBI's commercial intelligence value proposition across oncology and primary care markets.

Emerging players

Advera Health Analytics: Specialty pharma evidence and drug safety data analytics platform. Comparable in being a focused B2B pharma data SaaS, though narrower in scope than GBI's four-product portfolio.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

GBI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GBI leadership team

Management profile

Number of profiles

Profiles1 record

GBI funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GBI M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GBI

What does GBI do?

Is GBI a public or private company?

GBI is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was GBI founded?

GBI was founded in 2002. It employs 51 to 100 people.

Where is GBI based?

GBI is headquartered in Shanghai, China, in the Asia region.

How does GBI make money?

One revenue line is on record: enterprise Software Subscriptions.

Who are GBI's main competitors?

Direct peers on record are Citeline (Pharma Intelligence), GlobalData, Definitive Healthcare, Evaluate (Norstella) and PharmCube (Pharnexcloud). Broad incumbents are IQVIA, Clarivate, Veeva Systems and Kantar Health (now part of Cerner/Oracle). Advera Health Analytics is listed as an emerging player.

Does GBI have an API?

No public API is recorded for GBI.

What industry is GBI in?

GBI's product category is Pharmaceutical and Medtech Market Intelligence. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HDAAAGAJ, B2B SaaS & Enterprise Personalization (CRM, Sales, Support). Its NAICS code is 513210.